238 related articles for article (PubMed ID: 34016142)
1. eIF6 promotes the malignant progression of human hepatocellular carcinoma via the mTOR signaling pathway.
Sun L; Liu S; Wang X; Zheng X; Chen Y; Shen H
J Transl Med; 2021 May; 19(1):216. PubMed ID: 34016142
[TBL] [Abstract][Full Text] [Related]
2. Long noncoding RNA PICSAR/miR-588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway.
Liu Z; Mo H; Sun L; Wang L; Chen T; Yao B; Liu R; Niu Y; Tu K; Xu Q; Yang N
Cancer Sci; 2020 Nov; 111(11):4118-4128. PubMed ID: 32860321
[TBL] [Abstract][Full Text] [Related]
3. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis.
Du P; Luo K; Li G; Zhu J; Xiao Q; Li Y; Zhang X
Int J Med Sci; 2021; 18(15):3588-3598. PubMed ID: 34522186
[No Abstract] [Full Text] [Related]
4. High expression of PDZ-binding kinase is correlated with poor prognosis and immune infiltrates in hepatocellular carcinoma.
Mu W; Xie Y; Li J; Yan R; Zhang J; Liu Y; Fan Y
World J Surg Oncol; 2022 Jan; 20(1):22. PubMed ID: 35065633
[TBL] [Abstract][Full Text] [Related]
5. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
Zhang Z; Zhu J; Huang Y; Li W; Cheng H
Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of FEN1 Is Associated with the Tumor Progression and Prognosis of Hepatocellular Carcinoma.
Zhang Y; Liu X; Liu L; Chen J; Hu Q; Shen S; Zhou Y; Chen S; Xue C; Cui G; Yu Z
Dis Markers; 2020; 2020():2514090. PubMed ID: 32399086
[TBL] [Abstract][Full Text] [Related]
7. New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors.
Golob-Schwarzl N; Krassnig S; Toeglhofer AM; Park YN; Gogg-Kamerer M; Vierlinger K; Schröder F; Rhee H; Schicho R; Fickert P; Haybaeck J
Eur J Cancer; 2017 Sep; 83():56-70. PubMed ID: 28715695
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of eIF6 Activity Reduces Hepatocellular Carcinoma Growth: An In Vivo and In Vitro Study.
Scagliola A; Miluzio A; Mori G; Ricciardi S; Oliveto S; Manfrini N; Biffo S
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887068
[TBL] [Abstract][Full Text] [Related]
9. MiR-92a-3p Promotes the Malignant Progression of Hepatocellular Carcinoma by Mediating the PI3K/AKT/mTOR Signaling Pathway.
Wang L; Cui M; Qu F; Cheng D; Yu J; Tang Z; Cheng L; Wei Y; Wu X; Liu X
Curr Pharm Des; 2021; 27(29):3244-3250. PubMed ID: 34126886
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of microRNA-regulated protein interaction network reveals the tumor suppressive role of microRNA-149 in human hepatocellular carcinoma via targeting AKT-mTOR pathway.
Zhang Y; Guo X; Xiong L; Yu L; Li Z; Guo Q; Li Z; Li B; Lin N
Mol Cancer; 2014 Nov; 13():253. PubMed ID: 25424347
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of Cyclin F in liver cancer predicts poor prognosis: A study based on TCGA database.
Zelong Y; Han Y; Ting G; Yifei W; Kun H; Haoran H; Yong C
Medicine (Baltimore); 2021 Aug; 100(31):e26623. PubMed ID: 34397798
[TBL] [Abstract][Full Text] [Related]
12. Correlation of LAGE3 with unfavorable prognosis and promoting tumor development in HCC via PI3K/AKT/mTOR and Ras/RAF/MAPK pathways.
Li Y; Xiong H
BMC Cancer; 2022 Mar; 22(1):298. PubMed ID: 35313850
[TBL] [Abstract][Full Text] [Related]
13. Abnormal Expression of Centromere Protein U Is Associated with Hepatocellular Cancer Progression.
Yu Y; Chen X; Zhang W; Liu J
Biomed Res Int; 2021; 2021():4051192. PubMed ID: 34957303
[TBL] [Abstract][Full Text] [Related]
14. UBE2O promotes hepatocellular carcinoma cell proliferation and invasion by regulating the AMPKα2/mTOR pathway.
Shi Z; Liu R; Lu Q; Zeng Z; Liu Y; Zhao J; Liu X; Li L; Huang H; Yao Y; Huang D; Xu Q
Int J Med Sci; 2021; 18(16):3749-3758. PubMed ID: 34790050
[TBL] [Abstract][Full Text] [Related]
15. Construction and validation of a three-microRNA signature as prognostic biomarker in patients with hepatocellular carcinoma.
Zhang X; Ma L; Zhai L; Chen D; Li Y; Shang Z; Zhang Z; Gao Y; Yang W; Li Y; Pan Y
Int J Med Sci; 2021; 18(4):984-999. PubMed ID: 33456356
[TBL] [Abstract][Full Text] [Related]
16. Integrated clinical and prognostic analyses of mTOR/Hippo pathway core genes in hepatocellular carcinoma.
Feng T; Chen P; Wang T; Lai C; Yao Y
J Physiol Biochem; 2024 May; 80(2):439-449. PubMed ID: 38468074
[TBL] [Abstract][Full Text] [Related]
17. LncRNA OR3A4 participates in the angiogenesis of hepatocellular carcinoma through modulating AGGF1/akt/mTOR pathway.
Li W; Fu Q; Man W; Guo H; Yang P
Eur J Pharmacol; 2019 Apr; 849():106-114. PubMed ID: 30710550
[TBL] [Abstract][Full Text] [Related]
18. Normal tissue adjacent to tumor expression profile analysis developed and validated a prognostic model based on Hippo-related genes in hepatocellular carcinoma.
Pan Q; Qin F; Yuan H; He B; Yang N; Zhang Y; Ren H; Zeng Y
Cancer Med; 2021 May; 10(9):3139-3152. PubMed ID: 33818013
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA LINC01503 promotes the progression of hepatocellular carcinoma via activating MAPK/ERK pathway.
Wang MR; Fang D; Di MP; Guan JL; Wang G; Liu L; Sheng JQ; Tian DA; Li PY
Int J Med Sci; 2020; 17(9):1224-1234. PubMed ID: 32547318
[No Abstract] [Full Text] [Related]
20. BUB1B promotes hepatocellular carcinoma progression via activation of the mTORC1 signaling pathway.
Qiu J; Zhang S; Wang P; Wang H; Sha B; Peng H; Ju Z; Rao J; Lu L
Cancer Med; 2020 Nov; 9(21):8159-8172. PubMed ID: 32977361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
